Active substances
Amoxicillin + Clavulanic acid
- SFDA 104
- US FDA 54
- Health Canada 28
- US price lines 16
- NHS prices 9
- WHO EML 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| AMOCLAN | 200,1000 mg,mg | Powder for injection · Parenteral use | 10 Vial | SAR 88.25 | Generic · Prescription | Hikma Pharmaceuticals PLC | Valid |
| AMOCLAN 1.2 GM VIAL | 1000,200 mg,mg | Powder for solution for injection/infusion · Parenteral use | 1 Vial | SAR 14.60 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| AMOXIPLUS 1.2GM Powder for injection | 1000,200 mg,mg | powder for solution for injection · Parenteral use | 50 Vial | SAR 333.00 | Generic · Prescription | ANTIBIOTIC S.E | Valid |
| AUGMENTIN 1 G TAB | 875,125 mg,mg | Tablet · Oral use | 14 Blister | SAR 78.30 | NCE · Prescription | GLAXO SAUDI ARABIA | Valid |
| AUGMENTIN 156 Mg-5 ML SUSPENSION | 125,31.25 mg,mg | Powder for oral suspension · Oral use | 1 Bottle | SAR 17.35 | NCE · Prescription | GLAXO SAUDI ARABIA | Valid |
| AUGMENTIN 228 MG-5ML SUSPENSION | 200,28.5 mg,mg | Suspension · Oral use | 1 Bottle | SAR 19.20 | NCE · Prescription | GLAXO SAUDI ARABIA | Valid |
| AUGMENTIN 312 MG-5ML SUSPENSION | 50,12.5 mg/ml,mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 32.55 | NCE · Prescription | GLAXO SAUDI ARABIA | Valid |
| AUGMENTIN 457MG-5ML SUSPENSION | 400,57 mg,mg | Suspension · Oral use | 1 Bottle | SAR 33.05 | NCE · Prescription | GLAXO SAUDI ARABIA | Valid |
| AUGMENTIN 625 MG TAB | 500,125 mg,mg | Tablet · Oral use | 20 Blister | SAR 63.80 | NCE · Prescription | GLAXO SAUDI ARABIA | Valid |
| AUGMENTIN ES SUSPENSION | 600,42.9 mg,mg | Powder for oral suspension · Oral use | 1 Bottle | SAR 32.65 | NCE · Prescription | GLAXO SAUDI ARABIA | Valid |
| AUGMENTIN INFANT DROP | 50,12.5 mg,mg | Powder for oral suspension · Oral use | 1 Bottle | SAR 19.10 | NCE · Prescription | GLAXO SAUDI ARABIA | Valid |
| AUGMENTIN TAB 375 MG | 250,125 mg,mg | Tablet · Oral use | 20 Blister | SAR 36.75 | NCE · Prescription | GLAXO SAUDI ARABIA | Valid |
| CLAVODAR 1GM F.C. TABLETS | 875,125 mg,mg | Tablet · Oral use | 14 Blister | SAR 44.60 | Generic · Prescription | DAR ALDAWA | Valid |
| CLAVODAR 457MG/5ML SUSPENSION | 80,11.4 mg/ml,mg/ml | Suspension · Oral use | 1 Bottle | SAR 16.50 | Generic · Prescription | DAR ALDAWA | Valid |
| CLAVODAR 625GM FILM COATED TABLET | 500,125 mg,mg | Film-coated tablet · Oral use | 20 Blister | SAR 24.80 | Generic · Prescription | DAR ALDAWA | Valid |
| CURAM 1.2GM POW. FOR SOLN. FOR INJECTION- INFUSION | 1000,200 mg,mg | Powder for solution for injection/infusion · Parenteral use | 10 Vial | SAR 94.85 | Generic · Prescription | SANDOZ | Valid |
| CURAM 156.25MG-5ML POWDER FOR SUSP | 125,31.25 mg,mg | Powder for oral suspension · Oral use | 1 Bottle | SAR 10.35 | Generic · Prescription | SANDOZ | Valid |
| CURAM 1GM TABLET | 875,125 mg,mg | Film-coated tablet · Oral use | 14 Blister | SAR 44.15 | Generic · Prescription | SANDOZ | Valid |
| CURAM 312.5 MG-5ML POWDER FOR SUSP | 250,62.5 mg,mg | Powder for oral suspension · Oral use | 100 Bottle | SAR 18.10 | Generic · Prescription | SANDOZ | Valid |
| CURAM 457MG-5ML POW. FOR ORAL SUSPENSION | 400,57 mg/ml,mg/ml | Powder for oral suspension · Oral use | 70 Bottle | SAR 18.35 | Generic · Prescription | SANDOZ | Valid |
| CURAM 600MG POW. FOR SOLN. FOR INJECTION- INFUSION | 500,100 mg,mg | Powder for solution for injection/infusion · Parenteral use | 10 Vial | SAR 46.90 | Generic · Prescription | SANDOZ | Valid |
| CURAM 625 MG F.C TAB | 500,125 mg,mg | Film-coated tablet · Oral use | 20 Blister | SAR 21.85 | Generic · Prescription | SANDOZ | Valid |
| Clavodar ES Suspension | 600,62.9 mg,mg | Powder for oral suspension · Oral use | 1 Bottle | SAR 29.40 | Generic · Prescription | DAR ALDAWA | Valid |
| GLOCLAV 1GM FILM COATED TABLETS | 875,125 mg,mg | Film-coated tablet · Oral use | 14 Blister | SAR 56.80 | Generic · Prescription | GLOBAL PHARMA | Valid |
| GLOCLAV 375MG TAB | 250,125 mg,mg | Film-coated tablet · Oral use | 20 Blister | SAR 27.70 | Generic · Prescription | GLOBAL PHARMA | Valid |
79 more — full table
Indications — CHI Daman Drug Formulary
ACUTE EXACERBATION OF BRONCHIECTASIS (NON-CYSTIC FIBROSIS); ACUTE PYELONEPHRITIS; BACTERIAL SKIN INFECTIONS - ERYSIPELAS AND CELLULITIS; BACTERIAL SKIN INFECTIONS - GAS GANGRENE; BACTERIAL SKIN INFECTIONS - IMPETIGO AND ECTHYMA; BACTERIAL TONSILLOPHARYNGITIS TREATMENT AND PREVENTION; COMMUNITY ACQUIRED PNEUMONEA; DENTAL ABSCESS; HOSPITAL AND VENTILATER ACQUIRED PNEUMONIA; OSTEOMYELITIS; OTITIS MEDIA; PHARYNGITIS; Pyogenic Arthritis; RECURRENT URINARY TRACT INFECTIONS (UTI); Septic Shock; SINUSITIS; TUBERCULOSIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| AUGMENTIN '125' | 125MG/5ML;EQ 31.25MG BASE/5ML | for suspension · oral | US ANTIBIOTICS | Prescription | 6 Aug 1984 |
| AUGMENTIN '250' | 250MG/5ML;EQ 62.5MG BASE/5ML | for suspension · oral | US ANTIBIOTICS | Prescription | 6 Aug 1984 |
| AUGMENTIN '875' | 875MG;EQ 125MG BASE | tablet · oral | US ANTIBIOTICS | Prescription | 13 Feb 1996 |
| AUGMENTIN ES-600 | 600MG/5ML;EQ 42.9MG BASE/5ML | for suspension · oral | US ANTIBIOTICS | Prescription | 22 Jun 2001 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | tablet · oral | SANDOZ | Prescription | 14 Mar 2002 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | 500MG;EQ 125MG BASE | tablet · oral | SANDOZ | Prescription | 15 Mar 2002 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | 200MG/5ML;EQ 28.5MG BASE/5ML; 400MG/5ML;EQ 57MG BASE/5ML | for suspension · oral | SANDOZ | Prescription | 5 Jun 2002 |
| AUGMENTIN XR | 1GM;EQ 62.5MG BASE | tablet, extended release · oral | US ANTIBIOTICS | Prescription | 25 Sep 2002 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | tablet · oral | CHARTWELL RX | Prescription | 29 Oct 2002 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | 500MG;EQ 125MG BASE | tablet · oral | CHARTWELL RX | Prescription | 30 Oct 2002 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | tablet · oral | SANDOZ INC | Prescription | 21 Nov 2002 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | 200MG/5ML;EQ 28.5MG BASE/5ML; 400MG/5ML;EQ 57MG BASE/5ML | for suspension · oral | SANDOZ INC | Prescription | 16 Dec 2002 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | 600MG/5ML;EQ 42.9MG BASE/5ML | for suspension · oral | CHARTWELL RX | Prescription | 12 Mar 2004 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | 200MG/5ML;EQ 28.5MG BASE/5ML; 400MG/5ML;EQ 57MG BASE/5ML | for suspension · oral | CHARTWELL RX | Prescription | 25 May 2004 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | 400MG/5ML;EQ 57MG BASE/5ML; 200MG/5ML;EQ 28.5MG BASE/5ML | for suspension · oral | HIKMA PHARMS | Prescription | 25 Jan 2005 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | 200MG;EQ 28.5MG BASE; 400MG;EQ 57MG BASE | tablet, chewable · oral | CHARTWELL RX | Prescription | 9 Feb 2005 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | 250MG;EQ 125MG BASE | tablet · oral | SANDOZ | Prescription | 23 Aug 2005 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | 600MG/5ML;EQ 42.9MG BASE/5ML | for suspension · oral | SANDOZ INC | Prescription | 13 Aug 2007 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | 600MG/5ML;EQ 42.9MG BASE/5ML | for suspension · oral | HIKMA PHARMS | Prescription | 9 Nov 2007 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | 250MG/5ML;EQ 62.5MG BASE/5ML | for suspension · oral | CIPLA | Prescription | 25 Nov 2008 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | 1GM;EQ 62.5MG BASE | tablet, extended release · oral | SANDOZ | Prescription | 21 Apr 2010 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | 200MG/5ML;EQ 28.5MG BASE/5ML; 400MG/5ML;EQ 57MG BASE/5ML | for suspension · oral | AUROBINDO PHARMA LTD | Prescription | 20 Dec 2011 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | 600MG/5ML;EQ 42.9MG BASE/5ML | for suspension · oral | AUROBINDO PHARMA LTD | Prescription | 20 Dec 2011 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | 875MG;EQ 125MG BASE | tablet · oral | AUROBINDO PHARMA LTD | Prescription | 20 Jan 2012 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | 250MG;EQ 125MG BASE; 500MG;EQ 125MG BASE | tablet · oral | AUROBINDO PHARMA LTD | Prescription | 20 Jan 2012 |
29 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AG-AMOXI CLAV | 02510634 | 125 MG; 500 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| AG-AMOXI CLAV | 02510642 | 875 MG; 125 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION | 02495910 | 500 MG / VIAL; 100 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION | 02495929 | 200 MG / VIAL; 1000 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION | 02495937 | 2000 MG / VIAL; 200 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| AMOXICILLIN/CLAV | 02536021 | 500 MG; 125 MG | TABLET · ORAL | SANIS HEALTH INC |
| AMOXICILLIN/CLAV | 02536048 | 125 MG; 875 MG | TABLET · ORAL | SANIS HEALTH INC |
| APO-AMOXI CLAV | 02243350 | 125 MG; 250 MG | TABLET · ORAL | APOTEX INC |
| APO-AMOXI CLAV | 02243351 | 500 MG; 125 MG | TABLET · ORAL | APOTEX INC |
| APO-AMOXI CLAV | 02245623 | 875 MG; 125 MG | TABLET · ORAL | APOTEX INC |
| AURO-AMOXICLAV | 02471671 | 250 MG; 125 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-AMOXICLAV | 02471698 | 500 MG; 125 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-AMOXICLAV | 02471701 | 875 MG; 125 MG | TABLET · ORAL | AURO PHARMA INC |
| CLAVULIN 125 F ORAL SUS | 01916882 | 31.25 MG / 5 ML; 125 MG / 5 ML | POWDER FOR SUSPENSION · ORAL | GLAXOSMITHKLINE INC |
| CLAVULIN 200 | 02238831 | 200 MG / 5 ML; 28.5 MG / 5 ML | POWDER FOR SUSPENSION · ORAL | GLAXOSMITHKLINE INC |
| CLAVULIN 250 F ORAL SUS | 01916874 | 62.5 MG / 5 ML; 250 MG / 5 ML | POWDER FOR SUSPENSION · ORAL | GLAXOSMITHKLINE INC |
| CLAVULIN 400 | 02238830 | 57 MG / 5 ML; 400 MG / 5 ML | POWDER FOR SUSPENSION · ORAL | GLAXOSMITHKLINE INC |
| JAMP AMOXI CLAV | 02508249 | 125 MG; 250 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP AMOXI CLAV | 02508257 | 500 MG; 125 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP AMOXI CLAV | 02508265 | 875 MG; 125 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP AMOXI CLAV SUSPENSION | 02539438 | 250 MG / 5 ML; 62.5 MG / 5 ML | POWDER FOR SUSPENSION · ORAL | JAMP PHARMA CORPORATION |
| JAMP AMOXI CLAV SUSPENSION | 02539446 | 400 MG / 5 ML; 57 MG / 5 ML | POWDER FOR SUSPENSION · ORAL | JAMP PHARMA CORPORATION |
| M-AMOXI CLAV | 02530694 | 400 MG / 5 ML; 57 MG / 5 ML | POWDER FOR SUSPENSION · ORAL | MANTRA PHARMA INC |
| M-AMOXI CLAV | 02542226 | 250 MG / 5 ML; 62.5 MG / 5 ML | POWDER FOR SUSPENSION · ORAL | MANTRA PHARMA INC |
| PRO-AMOXI CLAV | 02536498 | 500 MG; 125 MG | TABLET · ORAL | PRO DOC LIMITEE |
3 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | AMOX-CLAV 200-28.5 MG/5 ML SUS | $0.04807 | per ML | 23 Sep 2026 |
| US NADAC | AMOX-CLAV 200-28.5 MG/5 ML SUS | $0.06998 | per ML | 23 Sep 2026 |
| US NADAC | AMOX-CLAV 200-28.5 MG/5 ML SUS | $0.05928 | per ML | 23 Sep 2026 |
| US NADAC | AMOX-CLAV 250-125 MG TABLET | $1.53115 | per EA | 23 Sep 2026 |
| US NADAC | AMOX-CLAV 250-62.5 MG/5 ML SUS | $0.45512 | per ML | 23 Sep 2026 |
| US NADAC | AMOX-CLAV 250-62.5 MG/5 ML SUS | $0.39204 | per ML | 23 Sep 2026 |
| US NADAC | AMOX-CLAV 250-62.5 MG/5 ML SUS | $0.43537 | per ML | 23 Sep 2026 |
| US NADAC | AMOX-CLAV 400-57 MG/5 ML SUSP | $0.05616 | per ML | 23 Sep 2026 |
| US NADAC | AMOX-CLAV 400-57 MG/5 ML SUSP | $0.08432 | per ML | 23 Sep 2026 |
| US NADAC | AMOX-CLAV 400-57 MG/5 ML SUSP | $0.06578 | per ML | 23 Sep 2026 |
| US NADAC | AMOX-CLAV 500-125 MG TABLET | $0.25341 | per EA | 23 Sep 2026 |
| US NADAC | AMOX-CLAV 600-42.9 MG/5 ML SUS | $0.0693 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Co-amoxiclav 125mg/31mg/5ml oral suspension | £3.54 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Co-amoxiclav 250mg/125mg tablets | £1.67 | 21 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Co-amoxiclav 250mg/62mg/5ml oral suspension | £3.60 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Co-amoxiclav 250mg/62mg/5ml oral suspension sugar free | £6.25 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Co-amoxiclav 400mg/57mg/5ml oral suspension | £4.13 | 35 ml | 1 Oct 2026 |
| NHS Drug Tariff | Co-amoxiclav 400mg/57mg/5ml oral suspension | £5.79 | 70 ml | 1 Oct 2026 |
| NHS Drug Tariff | Co-amoxiclav 400mg/57mg/5ml oral suspension sugar free | £3.49 | 70 ml | 1 Oct 2026 |
| NHS Drug Tariff | Co-amoxiclav 500mg/125mg tablets | £1.98 | 21 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Co-amoxiclav 875mg/125mg tablets | £5.99 | 14 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.1. Access group antibiotics · core
First choice: Bacterial pneumonia (Community-acquired pneumonia - severe) [children]; First choice: Acute sinusitis; First choice: Other specified pneumonia (Hospital-acquired pneumonia); First choice: Chronic obstructive pulmonary disease with acute exacerbation; First choice: Neutropaenia (low-risk); First choice: Peritoneal abscess (mild-moderate); First choice: Peritonitis (mild-moderate); First choice: Infectious cystitis; First choice: Bacterial cellulitis, erysipelas or lymphangitis; Second choice: Bacterial pneumonia (Community-acquired pneumonia - mild to moderate); Second choice: Bacterial pneumonia (Community-acquired pneumonia - severe); Second choice: Bacterial infection of joint; Second choice: Acute otitis media; Second choice: Other specified prophylactic measures; Second choice: Osteomyelitis or osteitis
Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection | Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid (EMLc); 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid (EMLc) | Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt) (EMLc); 250 mg (as trihydrate) + 62.5 mg (as potassium salt) (EMLc) | Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt) (EML) | Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt) - 6.2.5. Antituberculosis medicines · core
Multi-drug resistant Mycobacterium tuberculosis
Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid (EMLc) | Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt) (EMLc) | Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.